Ketoconazole-tacrolimus coadministration in kidney transplant recipients: Two-year results of a prospective randomized study

American Journal of Nephrology

Volumn 26, Issue 3, 2006, Pages 293-298

  El Dahshan, Khalid Farouk ^a   Bakr, Mohamed Adel ^a   Donia, Ahmed Farouk ^a   Badr, Ali El Sayed ^a   Sobh, Mohamed Abdel Kader ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Ketoconazole tacrolimus kidney transplant

Indexed keywords

ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; IMMUNOSUPPRESSIVE AGENT; INSULIN; KETOCONAZOLE; TACROLIMUS; TERBINAFINE;

ADOLESCENT; ADULT; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; CREAM; DERMATOMYCOSIS; DIABETES MELLITUS; DRUG COST; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INSULIN TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; DRUG COMBINATIONS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KETOCONAZOLE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TREATMENT OUTCOME;

EID: 33746342109     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094133     Document Type: Article

References (18)

1. Singh P, Bhandari M: Renal replacement therapy options from an Indian perspective: dialysis versus transplantation. Transplant Proc 2004;36:2013-2014.
2. El-Dahshan KF, Bakr MA, Donia AF, Badr AE, Sobh MA: Co-administration of ketoconazole to tacrolimus-treated kidney transplant recipients: a prospective randomized study. Nephrol Dial Transplant 2004;19:1613-1617.
3. 14C- labeled tacrolimus after intravenous and oral administration in healthy subjects. Drug Metab Dispos 1999;27:633-636.
4. Ferguson RM, Sutherland DER, Simmons RL, Najarian JS: Ketoconazole, cyclosporine metabolism and renal transplantation. Lancet 1982;ii:882-883.
5. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ: The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;85:15.
6. Tuteja S, Alloway RR, Johnson JA, Gaber AO: The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001;71:1303-1307.
7. Sobh M, El-Agroudy A, Moustafa F, Harras F, El-Bedewy M, Ghoneim M: Coadministration of ketoconazole to cyclosporin-treated kidney transplant recipients: a prospective randomized study. Am J Nephrol 1995;15:493-499.
8. Sobh M, Hamdy A, El-Agroudy A, El-Sayed K, El-Diasty T, Bakr M, Ghoneim M: Co-administration of ketoconazole and cyclosporine for kidney transplantations: long-term follow-up and study of metabolic consequences. Am J Kidney Dis 2001;37:510-517.
9. El-Agroudy A, Sobh M, Hamdy A, Ghoneim M: A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up. Transplantation 2004;77:1371-1376.
10. Soltero L, Carbajal H, Rodbriguez-Montalvo C, Valdes A: Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects. Transplant Proc 2003;35:1319-1321.
11. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y, et al: The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713-723.
12. Jones HE: Ketoconazole Today: a Review of Clinical Experience. Manchester, Adies Press, 1987, pp 8-21.
13. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG: Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology 1984;86:503-507.
14. Emre S, Genyk Y, Schluger LK: Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transplant Int 2000;13:73-78.
15. Van Hooff JP, Van Duijnhoven EM, Christiaans MHL: Tacrolimus and glucose metabolism. Transplant Proc 1999;31(suppl 7A):49S-50S.
16. Oka K, Moriyama T, Imai E, et al: A case of tacrolimus nephrotoxicity appearing in second renal transplantation patient. Clin Transplant 2001;15:30-34.
17. Glynn AM, Slaughter RL, Brass C, D'Ambrosio R, Jusko WJ: Effects of ketoconazole on methlyprednisolone pharmacokinetic and cortisol secretion. Clin Pharmacol Ther 1986;39:654-659.
18. Vuddhakul V, McCormack JG, Seow WK, Thong YH: Effects of the newer antifungal agents (bifonazole, ICI 195, 739 and amorolfin) on in vitro phagocytic, lymphocytic and natural-killer cell responses. Int J Immunopharmacol 1989;11:817-828.